{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:20:06Z","timestamp":1787678406017,"version":"build-2784847793"},"reference-count":7,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["public health action"],"accepted":{"date-parts":[[2025,4,30]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>To support BPaL (bedaquiline [Bdq], pretomanid [Pa] and linezolid [Lzd]) rollout, countries require ongoing technical and policy support for standardized drug susceptibility testing (DST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The Leveraging Innovation for the Faster Treatment of Tuberculosis (LIFT-TB) operational research project aimed to strengthen laboratory capacity for DST in 7 countries (the Philippines, Myanmar, Indonesia, Vietnam, Uzbekistan, Kyrgyzstan and Ukraine) through needs assessments, reagent and equipment support, quality control and training.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>During the project, we trained 157 professionals in phenotypic and molecular DST, enhancing quality assurance and implementation. We found there was variable DST capacity and resistance patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Our study highlights the need for continued investment in training and infrastructure to integrate DST into routine diagnostics and to support scale-up of BPaL regimens in high TB-burden settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5588\/pha.25.0014","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:31:22Z","timestamp":1764909082000},"page":"145-148","source":"Crossref","is-referenced-by-count":0,"title":["Laboratory strengthening strategies to advance drug susceptibility testing for BPaL regimens in TB treatment"],"prefix":"10.5588","volume":"15","author":[{"given":"J-K.","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Slyzkyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.F.","family":"Wares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2026082509213630000_15.4.145.1","unstructured":"World Health Organization . Global Tuberculosis Report 2024. Geneva: WHO, 2024."},{"key":"2026082509213630000_15.4.145.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2026082509213630000_15.4.145.3","unstructured":"World Health Organization . WHO Consolidated Guidelines on Tuberculosis_Module 4: Drug Resistant Tuberculosis Treatment. Geneva: WHO, 2020."},{"key":"2026082509213630000_15.4.145.4","unstructured":"World Health Organization. Web Annex B . Critical Concentrations for Pretomanid and Cycloserine: WHO Policy Statement. In: WHO Operational Handbook on Tuberculosis. Module 3: Diagnosis - Rapid Diagnostics for Tuberculosis Detection, Third Edition. Geneva: WHO, 2023."},{"key":"2026082509213630000_15.4.145.5","unstructured":"World Health Organization . WHO Operational Handbook on Tuberculosis. Module 4: Treatment-Drug-Resistant Tuberculosis Treatment. Geneva: WHO, 2022."},{"key":"2026082509213630000_15.4.145.6","unstructured":"World Health Organization . Use of Targeted Next-Generation Sequencing to Detect Drug-Resistant Tuberculosis: Rapid Communication, July 2023. Geneva: WHO, 2023."},{"key":"2026082509213630000_15.4.145.7","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.22.0138"}],"container-title":["Public Health Action"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/pha.25.0014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:21:47Z","timestamp":1787674907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/pha.25.0014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":7,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.5588\/pha.25.0014"],"URL":"https:\/\/doi.org\/10.5588\/pha.25.0014","relation":{},"ISSN":["2220-8372"],"issn-type":[{"value":"2220-8372","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}